Sarepta Therapeutics Inc Stock Nasdaq
Equities
US0023461041
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 1.85B | Sales 2025 * | 2.9B | Capitalization | 11.66B |
---|---|---|---|---|---|
Net income 2024 * | 214M | Net income 2025 * | 1B | EV / Sales 2024 * | 5.65 x |
Net cash position 2024 * | 1.2B | Net cash position 2025 * | 2.59B | EV / Sales 2025 * | 3.13 x |
P/E ratio 2024 * |
54.5
x | P/E ratio 2025 * |
11.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.22% |
Latest transcript on Sarepta Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
1st Jan change | Capi. | |
---|---|---|
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.46% | 22.2B | |
-16.53% | 21.23B | |
-9.03% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
-24.93% | 8.22B |